Financial Ratios

PARABOLIC DRUGS LTD.

NSE : PARABDRUGSBSE : 533211ISIN CODE : INE618H01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE5.700 (0 %)
PREV CLOSE ( ) 5.70
OPEN PRICE ( ) 5.70
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 21
TODAY'S LOW / HIGH ( )5.70 5.70
52 WK LOW / HIGH ( )5.7 5.7
NSE5.500 (0 %)
PREV CLOSE( ) 5.50
OPEN PRICE ( ) 5.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 5.50 (24000)
VOLUME 123
TODAY'S LOW / HIGH( ) 5.50 5.50
52 WK LOW / HIGH ( )5.5 5.5
Select year
ParticularsMar2018Mar2017Mar2016Mar2015Mar2014
Operational & Financial Ratios
   Earnings Per Share (Rs)-9.21-17.46-78.39-61.29-21.28
   CEPS(Rs)-5.72-13.93-74.75-57.44-18.23
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-141.30-134.18-121.83-50.633.12
   Tax Rate(%)-3.18-2.91-0.92-52.3440.13
Margin Ratios
   Core EBITDA Margin(%)-39.28-104.92-415.39-52.58-28.78
   EBIT Margin(%)-63.36-128.79-441.73-61.87-30.15
   Pre Tax Margin(%)-76.09-142.45-569.13-102.50-48.44
   PAT Margin (%)-78.52-146.59-574.37-156.14-29.00
   Cash Profit Margin (%)-48.78-116.95-547.67-146.34-24.84
Performance Ratios
   ROA(%)-12.50-20.19-63.54-36.61-11.37
   ROE(%)0.000.000.000.00-209.38
   ROCE(%)-29.62-45.35-81.66-19.30-15.36
   Asset Turnover(x)0.160.140.110.230.39
   Sales/Fixed Asset(x)0.150.150.170.551.16
   Working Capital/Sales(x)-0.23-0.25-0.24-2.337.64
Efficiency Ratios
   Fixed Capital/Sales(x)6.646.555.741.820.86
   Receivable days240.79339.20363.19185.58115.53
   Inventory Days78.26137.02768.01513.07288.74
   Payable days537.04395.15108.54207.89155.29
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-1.30-0.62-0.07-0.16-0.24
   Price/Book(x)-0.05-0.06-0.04-0.181.43
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)14.1814.0113.294.361.97
   EV/Core EBITDA(x)-42.17-14.13-2.87-7.99-7.31
   EV/EBIT(x)-22.38-10.88-2.69-6.73-6.31
   EV/CE(x)2.462.091.741.060.77
   M Cap / Sales0.640.730.440.240.06
Growth Ratio
   Net Sales Growth(%)-1.52-2.48-67.38-47.07-42.81
   Core EBITDA Growth(%)66.6179.15-177.17-7.13-11.90
   EBIT Growth(%)51.5674.55-148.24-9.76-11.97
   PAT Growth(%)47.2577.73-27.91-187.955.74
   EPS Growth(%)47.2577.73-27.91-187.955.74
Financial Stability Ratios
   Total Debt/Equity(x)-1.13-1.18-1.29-3.0643.62
   Current Ratio(x)0.200.280.300.811.12
   Quick Ratio(x)0.160.250.210.240.39
   Interest Cover(x)-4.97-9.43-3.47-1.52-1.65
   Total Debt/Mcap(x)21.3418.2329.0816.8930.57

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.